Ceftobiprole review

José Barberán

Possible clinical indications of ceftobiprole

Servicio de Medicina Interna - Enfermedades infecciosas, Hospital Universitario HM Montepríncipe, Universidad San Pablo CEU. Madrid, Spain

ABSTRACT

Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of adult community-acquired pneumonia and non-ventilator associated hospital-acquired pneumonia. However, its microbiological and pharmacokinetic profile is very attractive as armamentarium for empirical monotherapy treatment in other infections too. Among these, the following scenarios could be considered complicated skin and soft tissue infections, moderate-severe diabetic foot infections without bone involvement, vascular-catheter-associated-bloodstream infections, and fever without apparent focus in the hospitalized patient without septic shock or profound immunosuppression.

Key words: ceftobiprole, skin soft tissue infections, diabetic foot infections, vascular-catheter-associated-bloodstream infections and fever without apparent focus.

INTRODUCTION

Ceftobiprole is a fifth-generation cephalosporin currently approved in major European countries for the treatment of adult community-acquired (CAP) and Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP) [1]. However, the safety profile of this molecule as demonstrated in clinical trials, along with its antimicrobial and pharmacokinetic profile [2, 3], makes it a very attractive treatment option as monotherapy for empirical treatment of infections in which many patients could benefit from this potential alternative, despite the lack of data from clinical trials and observational studies.

Ceftobiprole is an extended-spectrum cephalosporin with demonstrated in vitro activity on the majority of Gram-positive cocci and aerobic Gram-negative bacilli of clinical relevance. On the former, it has heightened bactericidal action and includes: 1) Staphylococcus spp., both methicillin- and vancomycin-resistant Staphylococcus aureus and coagulase-negative staphylococci, 2) Streptococcus spp., including Streptococcus pneumoniae resistant to penicillins and third-generation cephalosporins, and 3) Enterococcus faecalis, as it is the first and only cephalosporin here with demonstrated activity. With regard to Gram-negative bacilli, its spectrum includes the majority of non-extended spectrum beta-lactamase (ESBL)-producing enterobacteria (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Proteus mirabilis), with activity similar to that of ceftazidime and ceftriaxone, and Pseudomonas aeruginosa, with similar activities to ceftazidime and cefepime [2].

OTHER POSSIBLE MONOTHERAPY INDICATIONS

The unique antibiotic spectrum of ceftobiprole, which for the first time combines activity against methicillin-resistant Staphylococcus spp. and P. aeruginosa, along with non-ESBL-producing enterobacteria, Streptococcus spp and E. faecalis, makes it a very attractive and advantageous monotherapy alternative compared to antibiotic combinations commonly used for empirical treatment of infections (table 1), which may be caused by one or several of the aforementioned microorganisms.

1. Complicated skin and soft tissue infections (cSSTs)

According to data from a pharmacovigilance study conducted in Europe over the course of 7 years, S. aureus was the primary agent in SSTIs (37.5%), of which 22.8% were MRSA. This was followed by P. aeruginosa (12%), E. coli (10.8%), and Enterococcus spp. (6.1%). Considering the polymicrobial aetiology and mechanisms of resistance that these microorganisms
Possible clinical indications of ceftobiprole

In this regard, within the vast group of SSTIs, the use of ceftobiprole should be considered in a) infections in areas with large prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA), which are severe and extensive and may be life-threatening, b) elderly patients with significant comorbidities (Child B or C cirrhosis of the liver, haemodialysis) or immunosuppression c) manipulated or previously treated chronic ulcers with signs of infection, and d) surgical or trauma wound infections [5].

The factors to bear in mind when selecting empirical treatment for these infections are the following: severity, history of infection/colonisation by resistant microorganisms, previous antibiotic treatment and local sensitivity patterns [6]. Recently, a prospective, observational Spanish study analysed bacteremia’s associated with pressure ulcers. The microorganisms most commonly isolated from blood were the following: *S. aureus* 17 (30%), *Proteus* spp. 16 (28%), *Bacteroides* spp. 13 (23%), *E. coli* 8 (14%) and *P. aeruginosa* 4 (7%). In 25% of cases, the infection was polymicrobial. Bacteremia-related mortality was 21% and was independently associated with nosocomial origin and polymicrobial aetiology [7].

Published data on experiences with ceftobiprole in this context is already available. In an experimental murine model of MRSA and *P. aeruginosa* infections, ceftobiprole achieved a significantly greater reduction in lesion volume and bacterial load than linezolid and vancomycin (in MRSA) and cefepime (in *P. aeruginosa*) [8].

The concentration of ceftobiprole (free drug) in subcutaneous cellular and musculoskeletal tissue, following a dose of 500 mg IV and determined in vivo by microdialysis, remains above 2 mg/L for at least 40% of the 8-hour interval between consecutive doses [9]. The cut-off points established by EUCAST, which determine the sensitivity of ceftobiprole, are as follows: *S. aureus* ≤2 mg/L, *S. pneumoniae* ≤0.5 mg/L, and *Enterobacteriacea* ≤0.25 mg/L [10].

The efficacy and safety of ceftobiprole in cSSTI was also assessed in two multi-centre, non-inferiority, phase-III, double-blind, and randomised clinical studies with over 1600 patients [11, 12]. In one study, ceftobiprole (500 mg/12 h IV) (n= 397) was compared to vancomycin (1000 mg/12 h IV) (n= 387) (1:1 ratio) for the duration of 7–14 days in infections due to Gram-positive microorganisms. Approximately 50% of the infections were abscesses, 30% wounds (surgical, traumatic and burns), and 20% cellulitis. Around 80% of infections were caused by *S. aureus* (1/3 MRSA). The clinical recovery rate was similar in clinically evaluable patients (>90%) and in the intent-to-treat analysis (77%). The same was observed in the rate of microbiological eradication (>90%). There were no differences in tolerability. The most common side effects of ceftobiprole were nausea (14%) and changes in taste (8%) [11].

The second study included Gram-positive and Gram-negative infections. Ceftobiprole (500 mg/8 h IV administered over a two-hour infusion) (n= 547) was compared with the combination of vancomycin (1000 mg/12 h IV) and ceftazidime 1000 mg/8 h IV (n=281) (2:1 ratio). The most common infections were: diabetic foot abscesses and infections (30%), wounds (surgical, traumatic, and burns), and cellulitis 20%. *S. aureus* was the most common causative microorganism (64%, 1/3 MRSA), followed by *E. coli* (10.7%) and *P. aeruginosa* (6.6%). The clinical recovery rate in clinically evaluable patients and in the intent-to-treat was similar (90.5% vs. 90.2% and 81.9% vs. 80.8%, respectively). There were neither differences observed in patients who experienced bacteremia in infections with severity criteria (CRP >50 mg/L, fascia or muscle involvement, with systemic inflammatory response syndrome or Panton-Valentine toxin-producing MRSA infection), nor by type of microorganism (Gram-positive 91.8% vs. 90.3%,

### Table 1: Possible indications of ceftobiprole

| Possible indications of ceftobiprole |
|-------------------------------------|
| 1. Community-acquired pneumonia, non-ventilator-associated hospital-acquired pneumonia |
| 2. Complicated skin and soft tissue infections |
| a) Infections in areas with high prevalence of methicillin-resistant *S. aureus* |
| - Severe and extensive, which may be life-threatening |
| - Elderly patient with significant comorbidity (Child B or C cirrhosis of the liver or haemodialysis) |
| - Immunosuppressed patient |
| b) Manipulated or previously treated chronic ulcers with signs of infection |
| c) Surgical or traumatic wound infections |
| 3. Moderate or severe diabetic foot infections without bone involvement |
| 4. Infection originating from a vascular catheter |
| 5. Fever with no apparent focus in hospitalised patient without septic shock or severe immunosuppression |
2. Moderate or severe diabetic foot infections without bone involvement

In Spain, the aetiology of diabetic foot infections has been well documented in recent studies. *S. aureus* (>30% MRSA) remains the most common agent, followed by Gram-negative bacilli (enterobacteria and *P. aeruginosa*) [16, 17].

The experience with ceftobiprole in diabetic foot infections has been analysed in detail. One three-year study examined the *in vitro* activity of ceftobiprole against 443 isolates (251 aerobic and 192 anaerobic) of complicated diabetic foot infections, in which it was demonstrated to be active against a wide range of aerobic and anaerobic Gram-positive and Gram-negative microorganisms. Ceftobiprole's activity was also compared with other antibiotics. In the case of aerobic Gram-positive cocci (*S. aureus*, including MRSA, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus lugdunensis*, *Streptococcus agalactiae* and other streptococci) ceftobiprole was more active than cefepime, ceftazidime, cefotaxime, cefoxitin, levofloxacin, linezolid, daptomycin and vancomycin [18]. Furthermore, in a multi-centre, double-blind, randomised clinical study on cSSTIs, in which ceftobiprole (500 mg/8 h) was compared to vancomycin (100 mg/12 h) plus ceftazidime (1000 mg/8 h), approximately one-third of the cases included were diabetic foot infections (n=257, 72% of these considered to be moderate or severe). The most frequently isolated microorganisms were: Methicillin-sensitive *S. aureus* (MSSA) 38%, MRSA 18%, *Enterobacter cloacae* 9%, *Streptococcus agalactiae* 9%, *P. aeruginosa* 8%, and *Proteus mirabilis* 7%. In this sub-population, the clinical recovery rates were as follows: 125/145, 86.2% for ceftobiprole and 63/77, 81.8% for vancomycin plus ceftazidime (mild infection 97.6% vs. 100% and severe infection 70.6% vs. 53.8%, respectively). However, the average duration of treatment was significantly shorter with ceftobiprole (8.7 vs. 9.5 days, respectively, p <0.05), suggesting a faster response to treatment when ceftobiprole is used [19].

3. Infections originating from vascular catheters

*S. aureus* (MRSA: 9.5-26.6%) and coagulase-negative staphylococci (methicillin-resistant: 53.4%) are the most common causative organisms of infections associated with venous catheters (central and peripheral) in our country [18-20]. However, in recent years a significant increase in Gram-negative bacilli has been reported, most notably *P. aeruginosa*, *E. coli* and *Klebsiella* spp., which have been associated to a significant degree with solid organ transplant, post-surgery, prior use of beta-lactams, prolonged hospital stay (>7-11 days), and more than 3 days post-catheter insertion [21, 22].

In this context, choosing ceftobiprole as monotherapy may replace the usual combinations of a glycopeptide with a beta-lactam, preferentially active against *P. aeruginosa*. Experience with ceftobiprole in the treatment of bacteraemia, although favourable, is still limited. In the first cSSTI study due to Gram-positive cocci, three episodes of staphylococcal bacteraemia (2 due to MRSA) treated with ceftobiprole resolved without complication [11]. In the other cSSTI study, 13 cases of bacteraemia were reported in the ceftobiprole group, 11 of which (84.6%) resolved. In the control group, 8 cases of bacteraemia were observed with favourable outcome in 62.5% (5/8) [12]. In the hospital-acquired pneumonia study, 41 cases of bacteraemia were identified in the ceftobiprole arm and 45 in the comparator group. The authors do not comment on the aetiology or clinical and microbiological outcomes in this sub-group [23]. In the community-acquired pneumonia clinical trial, several cases of bacteraemia are described with no mention of causal agents. The recovery rate in this subpopulation does not differ between treatment groups or in comparison to treated cases without bacteraemia (ceftobiprole 6/7, 85.7%, comparator 12/14, 85.7%) [24]. Also at this time there is a phase III ongoing study in *S. aureus* bacteraemia. The purpose of this study is to compare the efficacy and safety of ceftobiprole medocaril versus daptomycin in the treatment of patients with complicated *S. aureus* bacteraemia [25].

4. Fever with no apparent focus in hospitalised patients

The first point to consider in this patient type is to determine whether the origin of the fever is infectious, thus evaluating the clinical, biological and imaging data that may suggest infection. The second aspect is taking culture samples prior to starting treatment. The third decision involves choosing the empirical antibiotic treatment, clouded by a lack of focality [26]. In a large number of patients, the origin may be the venous catheter. In any case, one must always consider the most prevalent microorganisms as a cause of infection in hospitalised patients (*S. aureus*, coagulase-negative staphylococci, *Enterococcus* spp., and Gram-negative bacteria (enterobacteria and *P. aeruginosa*) which depend on the comorbidity, the invasive diagnostic or therapeutic procedures performed, and local epidemiology [27]. Furthermore, one must consider the risk of resistance, which is closely related to prior use of antibiotics, loss of colonisation immunity and colonisation pressure [28]. In patients without significant immunosuppression or septic shock, ceftobiprole may be used empirically as monotherapy with the goal of addressing the possible role of methicillin-resistant *Staphylococcus* spp., *E. faecalis*, *P. aeruginosa* and non-ESBL-producing enterobacteria.
CONCLUSIONS

Ceftobiprole may be a good therapeutic alternative for the empirical treatment of cSSTIs, including those involving diabetic foot, vascular catheter, and fever with no apparent infectious origin, which require hospitalisation and have risk factors for MRSA and *P. aeruginosa*. Always within the treatment protocols established at each hospital.

REFERENCES

1. https://cima.aemps.es/cima/pdfs/es/ft/78691/78691_ft.pdf
2. Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis. 2018; 91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020.
3. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47(1):21–33. DOI:10.2165/00003088-200847010-00003
4. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007; 57:7–13. DOI:10.1016/j.diagmicrobio.2006.05.009
5. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl 3):i35–44. doi:10.1093/jac/djkq302
6. Lipsky BA, Dryden M, Gottrup F, Nathwani D, Seaton RA, Stryj J. Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. J Antimicrob Chemother 2016; 71: 3026–3035. DOI:10.1093/jac/dkw287
7. Espejo E, Andrés M, Borrallo RM, Padilla E, García-Restoy E, Bella F and Complex Wounds Working Group. Bacteremia associated with pressure ulcers: a prospective cohort study. Eur J Clin Microbiol Infect Dis 2018; 37 (5):969–75. doi:10.1007/s10096-018-3216-8.
8. Fernández J, Hilliard JJ, Abbanat D, Zhang W, Melton JI, Santoro CM et al. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and *Pseudomonas aeruginosa*. Antimicrobial Agents Chemother 2010; 54:116–25. doi:10.1128/AAC.00642-09.
9. Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrobial Agents Chemother 2009; 53:2773–76. doi:10.1128/AAC.01409-08
10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0. 2018. http://www.eucast.org.

11. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrobial Agents Chemother 2008; 52:37e44. DOI:10.1128/AAC.00551-07
12. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647e55. doi:10.1086/526527.
13. FDA issues ceftobiprole Complete Response Letter [Internet]. Basilea Pharm. Ltd. (2009). Available from: http://www.basilea.com/News-and-Media/FDA-issues-ceftobiprole-Complete-Response-Letter/317.
14. European Medicines Agency. Refusal Assessment Report For Zeftera (previously known as Zeftera).
15. https://clinicaltrials.gov/ct2/show/NCT03137173?term=Ceftobiprole
draw=3&rank=11
16. de Alcalá Martínez-Gómez D, Ramírez-Almagro C, Campillo-Soto A, Morales-Cuenca G, Pagán-Ortiz, Aguayo-Albasini JL. Infecciones del pie diabético [Diabetic foot infections]. Prevalencia de los distintos microorganismos y sensibilidad a los antimicrobianos [Prevalence of different microorganisms and sensitivity to antibiotics]. Enferm Infecc Microbiol Clin. 2009; 27:317–321. DOI:10.1016/j.eimc.2008.07.004
17. Barberán J, Granizo JJ, Aguilar L, Alguacil R, Sainz F, Menéndez MA et al. Predictive model of short-term amputation during hospitalization of patients due to acute diabetic foot infections. Enferm Infecc Microbiol Clin. 2010; 28:680–4. DOI:10.1016/j.eimc.2009.12.017
18. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrell KL, Fernández HL. In vitro activity of ceftobiprole against aerobic and anaerobic bacilli isolated from diabetic foot infections. Antimicrobial Agents Chemother 2006; 50: 3599–62. doi:10.1128/AAC.00722-06
19. Deresinski SD. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008; 61(1):103–9. doi:10.1016/j.diagmicrobio.2008.03.004.
20. Marcos M, Soriano A, Illurrieta A, Martínez JA, Romero A, Cobos N et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother. 2011 Sep;66(9):2119-25. doi:10.1093/jac/dkr231.
21. Guembe M, Pérez-Granada MJ, Capdevila JA, Barberán J, Pinilla B, Martín-Rabadán P et al. Nationwide study on peripheral-vein catheter-associated-bloodstream infections in internal medicine departments. J Hosp Infect. 2017; 97(3):260-266. doi:10.1016/j.jhin.2017.07.008.
22. Ripa M, Morata L, Rodríguez-Núñez O, Cardozo C, Puerta-Alcalde P, Hernández-Meneses M et al. Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study, Antimicrob Agents Chemother. 2018; 62(11). pii: e00892-18. doi:10.1128/AAC.00892-18.
23. Awad SS, Rodríguez AH, Chuang YC, Marjanez Z, Pareigs AJ, Reis G et al. A phase 3 randomized double-blind comparison of ceftobipro medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59(1):51–61. DOI:10.1093/cid/ciu219
24. Nicholson SC, Welte T, File TM Jr, Strauss RS, Michiels B, Kaul P et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012 Mar;39(3):240-6. doi: 10.1016/j.ijantimicag.2011.11.005.

25. Tamma PD, Miller MA, Cosgrove SE. JAMA 2018 Dec 27. doi: 10.1001/jama.2018.19509.

26. EPINE-EPPS Study 2017. http://hws.vhebron.net/epine/Global/EPINE-EPPS%202017%20Informe%20Global%20de%20Espa%C3%B1a%20Resumen.pdf

27. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016; 316(11):1193-1204. DOI: 10.1001/jama.2016.11764